



## Ensifentrine for Maintenance of Chronic Obstructive Pulmonary Disease: Effectiveness and Value

Friday • June 14, 2024 • 10:00 – 4:00 PM CT

Virtual Event – Zoom Webinar

Registration: [https://events.zoom.us/ev/AjvH\\_C9SE5yWwzv4HKS4HGIUanQSoQWrBm7Ua-Cz\\_8Nc2SyBpFeU~Ai7Bqi\\_rmu8qtYoVjzPKbrpt2Ej06PKyWJaYLRM2vz2Q1GRi7HMaTfIKgg](https://events.zoom.us/ev/AjvH_C9SE5yWwzv4HKS4HGIUanQSoQWrBm7Ua-Cz_8Nc2SyBpFeU~Ai7Bqi_rmu8qtYoVjzPKbrpt2Ej06PKyWJaYLRM2vz2Q1GRi7HMaTfIKgg)

Time (CT)	Activity
<b>10:00 AM – 10:20 AM</b>	<b>Meeting Convened and Opening Remarks</b> Sarah K. Emond, MPP President and CEO, ICER  Steven D. Pearson, MD, MSc Special Advisor, ICER
<b>10:20 AM – 11:00 AM</b>	<b>Presentation of the Clinical Evidence</b> Grace Lin, MD, MAS Medical Director for Health Technology Assessment, ICER Associate Professor of Medicine and Health Policy, UCSF
<b>11:00 AM – 11:40 AM</b>	<b>Presentation of the Economic Model</b> Melanie D. Whittington, PhD, MS Senior Fellow, Center for the Evaluation of Value and Risk in Health, Tufts Medical Center
<b>11:40 AM – 12:00 PM</b>	<b>Public Comments and Discussion</b>
<b>12:00 PM – 12:50 PM</b>	<b>Lunch Break</b>
<b>12:50 PM – 1:50 PM</b>	<b>Midwest CEPAC Vote on Clinical Effectiveness and Value</b>
<b>1:50 PM – 2:00 PM</b>	<b>Break</b>
<b>2:00 PM – 3:30 PM</b>	<b>Policy Roundtable</b>
<b>3:30 PM – 4:00 PM</b>	<b>Reflections from Midwest CEPAC</b>
<b>4:00 PM</b>	<b>Meeting Adjourned</b>

ICER Staff and Consultants	
<b>Sarah Emond, MPP</b> , President and CEO, ICER	<b>Grace Ham, MSc</b> , Program and Events Coordinator, ICER
<b>Grace Lin, MD</b> , Medical Director for Health Technology Assessment, ICER	<b>Avery McKenna, BS</b> , Research Lead, ICER
<b>Steve Pearson, MD, MSc</b> , Special Advisor, ICER	<b>Finn Raymond, BS</b> , Research Assistant, ICER
<b>David Rind, MD, MSc</b> , Chief Medical Officer, ICER	<b>Liis Shea, MA</b> , Senior Program Director, ICER
<b>Mel Whittington, PhD, MS</b> , Senior Fellow Center for the Evaluation of Value and Risk in Health (CEVR), Tufts Medical Center	<b>Abigail Wright, PhD, MSc</b> , Research Lead, ICER

\*No conflicts of interest to disclose, defined as individual health care stock ownership in any health plan or pharmaceutical, biotechnology, or medical device manufacturers, or any health care consultant income or honoraria from health plans or manufacturers.

Participating Members of Midwest CEPAC	
<b>Eric Ambrecht, PhD</b> , Professor, Saint Louis University	<b>Bijan Borah, PhD</b> , Professor of Health Services Research, Mayo Clinic College of Medicine and Science
<b>Kurt Vanden Bosch, PharmD</b> , System Formulary Lead, St. Luke's Health System	<b>Don Casey, MD, MPH, MBA, MACP, FAHA</b> , Associate Professor of Internal Medicine, Rush Medical College
<b>Yngve Falck-Ytter, MD AGAF</b> , Case Western Reserve University	<b>Elbert Huang MD</b> , Professor of Medicine and Public Health Sciences, University of Chicago
<b>Jayani Jayawardhana, PhD</b> , Associate Professor, University of Kentucky	<b>Jill Johnson, PharmD</b> , Professor, UAMS College of Pharmacy
<b>David D Kim, PhD</b> , Assistant Professor, University of Chicago	<b>Bradley Martin, PharmD, PhD</b> , Professor, Division of Pharmaceutical Evaluation and Policy, University of Arkansas for Medical Sciences College of Pharmacy
<b>Tim McBride, PhD</b> , Professor, Washington University in St. Louis	<b>Jimi Olaghere</b> , Patient Advocate
<b>Rachel Sachs, JD, MPH</b> , "Professor of Law, Washington University in St. Louis"	<b>Timothy J. Wilt, MD, MPH</b> , Professor of Medicine and Public Health, University of Minnesota Schools of Medicine and Public Health and the Minneapolis VA Health Care System
<b>Stuart Winston, DO</b> , Patient Experience Consultant, Trinity-Health IHA Medical Group	

\*No conflicts of interest to disclose, defined as individual health care stock ownership (including anyone in the member's household) in any company with a product under study, including comparators, at the meeting in excess of \$10,000 during the previous year, or any health care consultancy income from the manufacturer of the product or comparators being evaluated.

Policy Roundtable Participant	Conflict of Interest
<b>Mindy Bauer, PharmD</b> , Pharmacist, IPD Analytics	Mindy Bauer is a full-time employee at IPD Analytics.
<b>Valerie Chang, BA, JD</b> , Executive Director, Hawaii COPD Coalition, Vice Chair of Board, COPD Foundation	Hawaii COPD Coalition receives annual sponsorships from a BCBS insurer and exhibit fees from pharmaceutical companies for the annual COPD Education Day. The COPD Foundation also receives greater than 25% of funding from health care companies.
<b>Stephanie Christenson, MD, MAS</b> , Associate Professor, Division of Pulmonary, Critical Care, Allergy, and Sleep Medicine, UCSF	Dr. Christenson reports grant support from the NIH, American Lung Association, COPD Foundation, and Department of Defense; consulting and advisory board fees from AstraZeneca, Sanofi, Regeneron, GSK, Verona Pharma, Glenmark Pharmaceuticals, Axon Advisors, Apogee Therapeutics, Amgen, Devpro Pharma, Kymera Therapeutics, and Genentech; Non-branded speaking fees from AstraZeneca, GSK, Sanofi, Regeneron, Amgen, Medscape, Horizon CME; writing fees from UpToDate.

<b>Phyllis DiLorenzo</b> , COPD Foundation Board Member	No personal conflicts to disclose. The COPD Foundation receives greater than 25% of funding from health care companies.
<b>David Dohan, MD</b> , Medical Director for Pharmacy and Appeals, Point34Health	Dr. Dohan is a full-time employee at Point34Health.
<b>Juan Rojas, MD, MS</b> , Director of Clinical Informatics & Data Science, Division of Translational & Precision Medicine, and Assistant Professor, Department of Internal Medicine, Division of Pulmonary, Critical Care, & Sleep Medicine, Rush University	No conflicts to disclose.